www.alopeciaworld.com
I have received a lot of interest from others on here in my involvement with the Xeljanz trials at Yale.
I thought it would be nice for everyone if I documented my progress on here.
Xeljanz is a Jak3 inhibitor and is believed to work with alopecia by turning off the distress signal relayed by the hair follicle to the attacking immune system which is the cause of the hairs falling out. Xeljanz comes in a strength of 5mg per pill and a full box contains 60 tablets. The recommended dosage for arthritis is 1 tablet in the morning and another in the evening each day.
The trial is set in a series of stages and there are requirements before participating. These include monthly visits and blood tests every 2 weeks. Dr Brett King is absolutely fantastic and is an inspiration to me. His positivity and enthusiasm gives me the much needed hope I have craved for over a decade. I have been put on a low dose to start with which is 1 tablet every other day. My dosage has now been increased to 1 tablet every day and next month it could be increased to 2 tablets per day depending on the results.
I have completed my first month and have already noticed my alopecia has stabilised . I have not lost any existing hairs. In addition to this I have seen little hairs growing in my chest area as well as eyebrows. Fingers crossed! To date, I have experienced no side effects.
-----------------------------
AW: Other discussions on Xeljanz / Tofacitinib
https://alopeciaworld.com/main/search/search?q=Tofacitinib
Tags:
I had attended an outreach session sponsored by FDA last week. I know it is not directly related to the use of Xeljanz, but thought you all may find this interesting.
Thank you for attending the public meeting on Patient-Focused Drug Development for Alopecia Areata last week! FDA collected valuable information on alopecia areata, the impact it has on patients’ lives, and patients’ perspectives on treatment options. We truly appreciate the courage, effort and time invested from everyone who was able to attend the meeting in person or on the web.
We know that not everyone who wanted to come to this meeting was able to attend. For anyone who missed the meeting or is interested in what was discussed, we have posted the meeting slides and a full recording of the meeting on our website: https://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm554443.htm.
In addition to the input we gathered at the meeting, we encourage individuals with alopecia areata and other stakeholders to submit written comments to the online public docket. The comment period closes on November 13, 2017. Submit your comments through this website: https://www.regulations.gov/doc ument?D=FDA-2017-N-3067-0001.
FDA is particularly interested in hearing patients’ perspectives on the discussion questions outlined in the Federal Register Notice that announced this meeting. These discussion questions are also pasted below for your reference.
Again, thank you to everyone who attended the meeting! If you have any questions, please email PatientFocused@fda.hhs.gov.
Any mention of products and services on Alopecia World is for informational purposes only; it does not imply a recommendation or endorsement by Alopecia World. Nor should any statement or representation on this site be construed as professional, medical or expert advice, or as pre-screened or endorsed by Alopecia World. Alopecia World is not responsible or liable for any of the views, opinions or conduct, online or offline, of any user or member of Alopecia World.
© 2024 Created by Alopecia World. Powered by